Akebia Therapeutics, Inc.
NASDAQ:AKBA · NASDAQ Global Market
+$0.01 today
Vol 22.76M · Avg 4.03M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:AKBA · Revenue to Net Income
Key Ratios
Analysis
$232.4M of revenue converted into -$20.5M of net income for the selected period. Gross margin is 80.7% and net margin is -9.2%, showing how much revenue survives after costs and taxes. EPS is $-0.08, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $236.2M +47.5% | $160.2M -17.7% | $194.6M -33.5% | $292.5M +38.2% | $211.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $39.5M -37.5% | $63.2M -14.8% | $74.1M +229.6% | $22.5M -72.4% | $81.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $196.7M +102.8% | $97.0M -19.5% | $120.5M -55.4% | $270.0M +107.4% | $130.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 83.3% +22.7pp | 60.6% -1.3pp | 61.9% -30.4pp | 92.3% +30.8pp | 61.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $62.4M +65.6% | $37.7M -40.3% | $63.1M -62.0% | $166.0M +12.3% | $147.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $107.5M +0.9% | $106.5M +6.3% | $100.2M -27.7% | $138.6M -20.4% | $174.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $173.2M +17.5% | $147.5M -11.5% | $166.7M -52.5% | $350.8M -11.1% | $394.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.3M -96.6% | $37.5M -0.3% | $37.6M -0.2% | $37.7M -0.7% | $38.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $21.7M +258.3% | -$13.7M -66.0% | -$8.3M -370.5% | $3.1M +101.6% | -$189.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 9.2% +17.8pp | -8.6% -4.3pp | -4.2% -5.3pp | 1.0% +90.8pp | -89.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | $23.5M +146.6% | -$50.5M -9.1% | -$46.3M +42.7% | -$80.8M +69.5% | -$264.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 9.9% +41.5pp | -31.5% -7.7pp | -23.8% +3.9pp | -27.6% +97.4pp | -125.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $24.2M +33.0% | $18.2M +201.5% | $6.0M -61.5% | $15.7M -21.3% | $19.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$27.2M -43.7% | -$18.9M -234.1% | -$5.7M +57.8% | -$13.4M +23.3% | -$17.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$3.7M +94.6% | -$69.4M -33.7% | -$51.9M +44.9% | -$94.2M +66.6% | -$282.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -1.6% +41.8pp | -43.3% -16.7pp | -26.7% +5.5pp | -32.2% +101.0pp | -133.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.6M | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$5.3M +92.3% | -$69.4M -33.7% | -$51.9M +44.9% | -$94.2M +66.6% | -$282.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -2.3% +41.1pp | -43.3% -16.7pp | -26.7% +5.5pp | -32.2% +101.0pp | -133.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +93.7% | -$0 -17.9% | -$0 +51.7% | -$1 +60.8% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +93.7% | -$0 -17.9% | -$0 +51.7% | -$1 +60.8% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $257.2M +21.9% | $210.9M +12.5% | $187.5M +2.6% | $182.8M +10.1% | $165.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $257.2M +21.9% | $210.9M +12.5% | $187.5M +2.6% | $182.8M +10.1% | $165.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$993.02M
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$801.81M
Zevra Therapeutics, Inc.
NASDAQ:ZVRA
$763.10M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$606.88M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$501.07M
Prothena Corporation plc
NASDAQ:PRTA
$463.33M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$280.72M
Gossamer Bio, Inc.
GOSS
$39.47M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does AKBA generate?
Akebia Therapeutics, Inc. (AKBA) reported $236.20M of revenue in fiscal 2025.
Is AKBA profitable?
Akebia Therapeutics, Inc. (AKBA) reported -$5,345,000.00 of net income, with a net margin of -2.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.